These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 27259295)
1. Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy. Sturm E; Fellner L; Krismer F; Poewe W; Wenning GK; Stefanova N Neurotherapeutics; 2016 Oct; 13(4):871-879. PubMed ID: 27259295 [TBL] [Abstract][Full Text] [Related]
2. Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications. Kaindlstorfer C; Sommer P; Georgievska B; Mather RJ; Kugler AR; Poewe W; Wenning GK; Stefanova N Neurotox Res; 2015 Oct; 28(3):185-94. PubMed ID: 26194617 [TBL] [Abstract][Full Text] [Related]
3. Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. Ubhi K; Rockenstein E; Mante M; Inglis C; Adame A; Patrick C; Whitney K; Masliah E J Neurosci; 2010 May; 30(18):6236-46. PubMed ID: 20445049 [TBL] [Abstract][Full Text] [Related]
4. Overexpression of α-Synuclein by Oligodendrocytes in Transgenic Mice Does Not Recapitulate the Fibrillar Aggregation Seen in Multiple System Atrophy. Laferrière F; He X; Zinghirino F; Doudnikoff E; Faggiani E; Meissner WG; Bezard E; De Giorgi F; Ichas F Cells; 2020 Oct; 9(11):. PubMed ID: 33138150 [TBL] [Abstract][Full Text] [Related]
5. Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies. Refolo V; Bez F; Polissidis A; Kuzdas-Wood D; Sturm E; Kamaratou M; Poewe W; Stefanis L; Angela Cenci M; Romero-Ramos M; Wenning GK; Stefanova N Acta Neuropathol Commun; 2018 Jan; 6(1):2. PubMed ID: 29298733 [TBL] [Abstract][Full Text] [Related]
6. Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. Stefanova N; Kaufmann WA; Humpel C; Poewe W; Wenning GK Acta Neuropathol; 2012 Jul; 124(1):51-65. PubMed ID: 22491959 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of FABP7 by MF 6 counteracts cerebellum dysfunction in an experimental multiple system atrophy mouse model. Cheng A; Jia W; Finkelstein DI; Stefanova N; Wang H; Sasaki T; Kawahata I; Fukunaga K Acta Pharmacol Sin; 2024 Jan; 45(1):66-75. PubMed ID: 37605049 [TBL] [Abstract][Full Text] [Related]
9. Is Multiple System Atrophy a Prion-like Disorder? Jellinger KA; Wenning GK; Stefanova N Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576255 [TBL] [Abstract][Full Text] [Related]
10. Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Heras-Garvin A; Weckbecker D; Ryazanov S; Leonov A; Griesinger C; Giese A; Wenning GK; Stefanova N Mov Disord; 2019 Feb; 34(2):255-263. PubMed ID: 30452793 [TBL] [Abstract][Full Text] [Related]
11. Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Bassil F; Fernagut PO; Bezard E; Pruvost A; Leste-Lasserre T; Hoang QQ; Ringe D; Petsko GA; Meissner WG Proc Natl Acad Sci U S A; 2016 Aug; 113(34):9593-8. PubMed ID: 27482103 [TBL] [Abstract][Full Text] [Related]
12. Age-related motor dysfunction and neuropathology in a transgenic mouse model of multiple system atrophy. Fernagut PO; Meissner WG; Biran M; Fantin M; Bassil F; Franconi JM; Tison F Synapse; 2014 Mar; 68(3):98-106. PubMed ID: 24243499 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of iron modulating drugs in a mouse model of multiple system atrophy. Shukla JJ; Stefanova N; Bush AI; McColl G; Finkelstein DI; McAllum EJ Neurobiol Dis; 2021 Nov; 159():105509. PubMed ID: 34537326 [TBL] [Abstract][Full Text] [Related]